Over 1Q25 Aalberts' topline came in as expected declining 3.3% in line with the issued 1Q guidance calling for a mid single organic revenue decline. Adjusted EBITA landed at €106m (vs. our €115mE and CSS of € 108mE). Overall EBITA margin of 13.6% (vs. 14% CSS, 14.2% KBCe) was down from 14.2% in 1Q24. Gross margin was said to be at a good level, which based on historical track record should thus hover around our estimated 62-63%. Company is not formally reiterating FY25 guidance issued last Febru...
Aalberts N.V.: Aalberts reports first quarter 2025 results Utrecht, 2 May 2025 Aalberts reports first quarter 2025 resultsIn the first quarter Aalberts realised EUR 778.3 million revenue, which translates into 3.3% organic revenue decline compared to the first quarter of last year. We realised EUR 105.7 million EBITA or 13.6% EBITA margin. In challenging market environments, we continued our focus on cost out and inventory optimisation initiatives. The added value margin remained on a good level. Thanks to our local footprint, supply chain and pricing excellence, we did not see a materia...
Printing Software saw a tough reference period with a large 5-year contract signed in 1Q24. However a 55% revenue decline is significantly worse than we expected. Printing Software revenues are lumpy, so potential for a catch up in the remainder of the year. In the other segments strong Printhead Solutions compensates for slightly weaker Enterprise Software. Management remains positive on 2025, highlighting healthy sales funnels across all segments.
Aalberts N.V.: Aalberts completes acquisition of Paulo Products Company Utrecht, 1 May 2025 Aalberts announces successful regulatory approval, finalising the acquisition of Paulo Products Company, operating five facilities in the USA and one in Mexico, generating an annual revenue of approximately USD 105 million with 522 employees. The results of Paulo will be consolidated as of 1 May 2025. In December 2024, Aalberts announced that agreement was reached to acquire Paulo Products Company, North America’s largest privately owned thermal processing platform, specializing in industrial heat...
argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025 May 1, 2025Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, May 8, 2025 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its first quarter 2025 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at . A replay of th...
Aalberts reports the progress of its share buyback programme 22 April – 25 April 2025 Utrecht, 29 April 2025 Aalberts today reports that it has repurchased 105,706 of its own shares in the period from 22 April 2025, up to and including 25 April 2025, for an amount of EUR 2,828,071.84, so at an average share price of EUR 26.75. This is part of the share buyback programme as announced on 27 February 2025, for a total amount of EUR 75 million. The repurchase of shares commenced on 28 February 2025 and will be completed no later than 24 October 2025. It is intended that the shares will be ca...
argenx received a positive opinion from the CHMP of the EMA for Vyvgart in treating CIDP in adults with progressive or relapsing disease after prior treatment with corticosteroids or immunoglobulins. The European Commission will now decide on the regulatory submission within 60 days. Vyvgart is the first novel CIDP treatment in over 30 years and could potentially be self-administered. This approval is expected to lead to significant sales in the EU, with EU peak sales estimated at $1.1bn (KBCSe...
argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) VYVGART® is first-and-only targeted IgG Fc-antibody fragment for CIDPFirst novel mechanism of action for CIDP treatment in more than 30 yearsCHMP positive opinion based on ADHERE data, the largest ever CIDP clinical trial European Commission (EC) decision on marketing authorization application (MAA) expected within approximately two months April 28, 2025, 07:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a...
A director at UCB SA bought 674 shares at 138.350EUR and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.